Placebo-controlled trial of the CCK-B antagonist, CI-988, in panic disorder

Biological Psychiatry

Volumn 46, Issue 6, 1999, Pages 860-862

  Pande, Atul C ^a   Greiner, Martha ^a   Bammert Adams, Judith ^a   Lydiard, R Bruce ^b   Pierce, Mark W ^a  

^a PFIZER INC   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Anxiety; Cholecystokinin antagonist; Panic; Pathophysiology

Indexed keywords

1 (2,3 DIHYDRO 1 METHYL 2 OXO 5 PHENYL 1H 1,4 BENZODIAZEPIN 3 YL) 3 (3 METHYLPHENYL)UREA; 4 [[2 [2 [[(2 ADAMANTYLOXY)CARBONYL]AMINO] 3 (1H INDOL 3 YL) 2 METHYLPROPIONAMIDO] 1 PHENYLETHYL]AMINO] 4 OXOBUTYRIC ACID MEGLUMINE; CHOLECYSTOKININ B RECEPTOR ANTAGONIST;

AGORAPHOBIA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; HUMAN; PANIC; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT FAILURE;

ADOLESCENT; ADULT; AGED; ANTI-ANXIETY AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; HUMANS; INDOLES; MEGLUMINE; MIDDLE AGED; PANIC DISORDER; RECEPTORS, CHOLECYSTOKININ;

EID: 0032842188     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-3223(99)00090-6     Document Type: Article

References (18)

1. Abelson J.L., Nesse R.M. Pentagastrin infusion in patients with panic disorder. I. Symptoms and cardiovascular responses. Biol Psychiatry. 36:1994;73-83.
2. Bammert Adams J., Pyke R., Costa J., Cutler N., Schweizer E., Wilcox C., Wisselink P., Greiner M., Pierce M.W., Pande A.C. Double-blind, placebo-controlled study of a CCK-B receptor antagonist, CI-988, in patients with Generalized Anxiety Disorder. J Clin Psychopharmacol. 15:1995;428-434.
3. Boden P.R., Higginbottom M., Hill D.R., Horwell D.C., Hughes J., Rees D.C., Roberts E., Singh L., Suman Chauhan N., Woodruff G.N. Cholecystokinin dipeptoid antagonists design, synthesis, and anxiolytic profile of some novel CCK A and CCK B selective and "mixed" CCK A/CCK B antagonists . J Med Chem. 36:1993;552-565.
4. Bradwejn J., Koszycki D. The cholecystokinin hypothesis of anxiety and panic disorder. Ann NY Acad Sci. 713:1994;273-282.
5. Bradwejn J., Koszycki D. Imipramine antagonism of the panicogenic effects of CCK-4 in panic disorder patients. Am J Psychiatry. 49:1994;318-323.
6. Bradwejn J., Koszycki D., Couëtoux du Tertre A., van Megen H., den Boer J., Westenberg H. The panicogenic effects of cholecystokinin tetrapeptide are antagonized by L-365,260, a central cholecystokinin receptor antagonist, in patients with panic disorder. Arch Gen Psychiatry. 51:1994;486-493.
7. Bradwejn J., Koszycki D., Paradis M., Reece P., Hinton J., Sedman A. Effect of CI-988 on cholecystokinin tetrapeptide-induced panic symptoms in healthy volunteers. Biol Psychiatry. 38:1995;742-746.
8. Brambilla F., Bellodi L., Perna G., Garberi A., Panerai A., Sacerdote P. Lymphocyte cholecystokinin concentrations in panic disorder. Am J Psychiatry. 150:1993;1111-1113.
9. Charrier D., Dangoumau L., Puech A.J., Hamon M., Thiébot M.-H. Failure of CCK receptor ligands to modify anxiety-related behavioural suppression in an operant conflict paradigm in rats. Psychopharmacology. 121:1995;127-134.
10. B receptor antagonists in ethological and conditioned animal screens for anxiolytic drugs. Psychopharmacology. 121:1995;109-117.
11. Kramer M.S., Cutler N.R., Ballenger J.C., Patterson W.M., Mendels J., Chenault A., Shrivastava R., Matzura-Wolfe D., Lines C., Reines S. A placebo-controlled trial of L-365,260, a CCK-B antagonist, in panic disorder. Biol Psychiatry. 37:1995;462-466.
12. Lydiard R.B., Ballenger J.C., Laraia M.T., Fossey M.D., Beinfeld M.C. CSF cholecystokinin concentrations in patients with panic disorder and in normal comparison subjects. Am J Psychiatry. 149:1992;691-693.
13. Rasmussen K., Helton D.R., Berger J.E., Scearce E. The CCK-B antagonist LY288513 blocks effects of diazepam withdrawal on auditory startle. Neuroreport. 5:1993;154-156.
14. Singh L., Lewis A.S., Field M.J., Hughes J., Woodruff G.N. Evidence for an involvement of the brain cholecystokinin B receptor in anxiety. Proc Natl Acad Sci USA. 88:1991;1130-1133.
15. van Megen H.J.G.M., Westenberg H.G.M., den Boer J.A. Effect of the cholecystokinin-B receptor antagonist L-365,260 on lactate-induced panic attacks in panic disorder patients. Biol Psychiatry. 40:1996;804-806.
16. van Megen H.J.G.M., Westenberg H.G.M., den Boer J.A. Pentagastrin induced panic attacks enhanced sensitivity in panic disorder patients . Psychopharmacology. 114:1994;449-455.
17. van Megen H.J.G.M., Westenberg H.G.M., den Boer J.A. Effect of the selective serotonin reuptake inhibitor (SSI) fluvoxamine on CCK-4 induced panic attacks. Psychopharmacology. 10:(Suppl):1994;270.
18. van Megen H.J.G.M., Westenberg H.G.M., den Boer J.A., Slaap B., van Es-Radhakishun F., Pande A.C. The cholecystokinin-B receptor antagonist CI-988 failed to affect CCK-4 induced symptoms in panic disorder patients. Psychopharmacology. 129:1997;243-248.